A must-attend event for any organisation seeking to bring their medicines, devices and diagnostics to UK patients.
Thank you to those who attended our Patient Access Conference on Wednesday 22nd September. It was a successful day with expert speakers from across the industry including patient groups who all shared their opinions, expertise, and passion for patient access.
We are currently pulling together the slide decks and recording of the sessions which will be available soon.
If you would like to register to receive this content, please complete the below form.
“Kept me interested throughout the day. Hearing how passionate the patient group representatives are especially re the importance of all the NICE methods review. Getting a chance to meet others working in market access was really useful”
“A good selection of speakers, relevant to the UK rare disease market access which is exactly my area of interest. Great patient group involvement with practical insights.”
“A good range of speakers and honest tone of the conference. The openness was refreshing as many of these the things aren’t shared in a public forum, yet many of us think this; thank you for the candour!”
“Great range of topics and diverse speakers and views. I really enjoyed the conference and am only sorry I couldn’t make it in person.”
For updates on our next conference and other events please sign up for our newsletters by emailing marketing@mappatientaccess.com
Developments in
strategy and HTA
The importance of patient engagement throughout the HTA process
Using patient registries in HTAs
Appraisal process of medical devices compared with drugs
Health economic modelling of digital apps
Access to Orphan Medicines: Developing policies for the future
Innovation tools
Approaches to utilising Real World Evidence (RWE)
Using analytics and big data to gain competitive advantage in Market Access
Collaborative working and horizon scanning
Harnessing digital systems and technology to find new levels of patient value
Pricing and policy
VPAS – what you need to know
Updates on The Commercial Framework
Advanced Therapy Medicinal Products – Responding to new high cost/high value drugs
The NHS Long Term Plan and what this actually means for pharma companies
Who should attend?
This conference should be attended by representatives from UK, European and global pharmaceutical, biotech, life science and MedTech industries, as well as patient organisations and patient groups.
The job functions that will benefit most include:
Heads of Market Access
Country Managers
Health Economists
Commercial Directors
Marketing Directors
Managing Directors
Chief Executives
Medical Directors
Policy Officers/Executives
Policy Advisors
Heads of Market Access
Country Managers
Health Economists
Commercial Directors
Marketing Directors
Managing Directors
Chief Executives
Medical Directors
Policy Officers/Executives
Policy Advisors
Expert speaker faculty
Andi Orlowski
Director of the Health Economics Unit (NHS)
Charlie Galvin
General Manager, UK and Ireland, Amicus and Board Member, Association of British Pharmaceutical Industry
Christian Hill
CEO, MAP BioPharma
Darren Spevick
Head of Europe, TSP and Chair of the EMIG Digital Health Special Interest Group
David Gillen
Global Head of Medical Affairs and Safety, Menarini Pharma
David Thomas
Co-Chair, Charity Medicines Access Coalition
David Watson
Director Pricing And Reimbursement, Association of the British Pharmaceutical Industry (ABPI)
Jasdeep Hayre
Associate Director, Technology Appraisals, NICE
Natalie Frankish
Policy and Engagement Manager, Genetic Alliance Virtual
Dr Thomas Kenny
CEO Rare Disease Research Partners, MPS Society
Tracey Bowden
Head of Policy and Public Affairs, MAP BioPharma
Samantha Barber
CEO, Gene People
Andi Orlowski
Director of the Health Economics Unit (NHS)
Charlie Galvin
General Manager, UK and Ireland, Amicus and
Board Member, Association of British Pharmaceutical Industry
Christian Hill
CEO, MAP BioPharma
Darren Spevick
Head of Europe, TSP and Chair of the EMIG Digital Health Special Interest Group
David Gillen
Global Head of Medical Affairs and Safety, Menarini Pharma
David Thomas
Co-Chair, Charity Medicines Access Coalition
David Watson
Director Pricing And Reimbursement, Association of the British Pharmaceutical Industry (ABPI)
Jasdeep Hayre
Associate Director, Technology Appraisals, NICE
Natalie Frankish
Policy and Engagement Manager, Genetic Alliance Virtual
Samantha Barber
CEO, Gene People
Dr Thomas Kenny
CEO Rare Disease Research Partners, MPS Society
Tracey Bowden
Head of Policy and Public Affairs, MAP BioPharma
Exhibitors
We are an independent horizon scanning centre based at Newcastle University in the UK. We use advanced horizon scanning techniques to detect new health innovations and track them; from patent-to-patient.
NICE provide UK national guidance for the NHS through their NICE technology appraisal (TA) and highly specialised technology (HST) process. NIHRIO is industry’s gateway to NICE, notifying NICE about new or repurposed drugs 3 years before UK license. This early notification allows NICE to provide new technology guidance as close to the license date as possible, ensuring efficient UK market access.
O4 Research is a UK/Ireland based provider of innovative, sector leading clinical trial services and ‘On & Off’ site management solutions. For over a decade we have successfully delivered full and functional services for Top 20 Pharma, biotech and medical device clients across Clinical Phases II-IV and RWE studies. We understand the value of RWE and its role in the development of new healthcare interventions. Our scientific expertise, combined with advances in data acquisition, mean we are ideally placed to help you deliver a bespoke solution for timely and compelling evidence generation. We take the complex and make it simple.
EUCOPE is Europe’s trade body for small to medium-sized innovative companies working in the field of pharmaceuticals and medical technologies.
Based in Brussels, EUCOPE gives voice to more than 900 research-oriented innovative companies and associations active in research, development of pharmaceuticals, biotechnologies and medical devices. Many of our members are developing therapeutic solutions for persons living with a rare disease, who had little to no treatment available just a few years ago.
We are an independent horizon scanning centre based at Newcastle University in the UK. We use advanced horizon scanning techniques to detect new health innovations and track them; from patent-to-patient.
NICE provide UK national guidance for the NHS through their NICE technology appraisal (TA) and highly specialised technology (HST) process. NIHRIO is industry’s gateway to NICE, notifying NICE about new or repurposed drugs 3 years before UK license. This early notification allows NICE to provide new technology guidance as close to the license date as possible, ensuring efficient UK market access.
O4 Research is a UK/Ireland based provider of innovative, sector leading clinical trial services and ‘On & Off’ site management solutions. For over a decade we have successfully delivered full and functional services for Top 20 Pharma, biotech and medical device clients across Clinical Phases II-IV and RWE studies. We understand the value of RWE and its role in the development of new healthcare interventions. Our scientific expertise, combined with advances in data acquisition, mean we are ideally placed to help you deliver a bespoke solution for timely and compelling evidence generation. We take the complex and make it simple.
EUCOPE is Europe’s trade body for small to medium-sized innovative companies working in the field of pharmaceuticals and medical technologies.
Based in Brussels, EUCOPE gives voice to more than 900 research-oriented innovative companies and associations active in research, development of pharmaceuticals, biotechnologies and medical devices. Many of our members are developing therapeutic solutions for persons living with a rare disease, who had little to no treatment available just a few years ago.
Agenda
Wednesday 22nd September - All times in BST.
Session One
08:30 – Morning coffee & registration
09:00 – Welcome to Patient Access 2021. Introductions and scene setting – Christian Hill, CEO MAP BioPharma
Developments in strategy for Patient Access
09:15 – The importance of patient engagement throughout the HTA process – David Thomas, Co-Chair, Charity Medicines Access Coalition and Natalie Frankish, Policy and Engagement Manager for Scotland, Genetic Alliance UK
09:45 – Using patient registries in HTAs – David Gillen, Global Head of Medical Affairs and Safety, Menarini Pharma
10:15 – Future development for Patient Access in new health technologies – Dr Grace Jennings, Head of MAP Online, MAP BioPharma
Break
10:45 – Refreshments & Networking; Guided tours of MAP Online resources and free consultation clinics; Meet our exhibitors: NIHR Innovation Observatory (NIHRIO); O4 Research; EUCOPE
Session Two
11:15 – Access to Orphan Medicines: Developing policies for the future – Policy and Public Affairs Team, MAP BioPharma
11:45 – Panel Discussion: Led by MAP’s Policy and Public Affairs team, this interactive session will bring together experts to consider challenges with and solutions for the appraisal of medicines for rare diseases.
Panellists will reflect on the potential for the NICE methods review, proposed Innovative Medicines Fund and other policy levers to improve access to orphan medicines arrangements. Our panel includes:
Dr Thomas Kenny, CEO Rare Disease Research Partners, MPS Society
Natalie Frankish, Policy and Engagement Manager, Genetic Alliance Virtual
Samantha Barber, CEO, Gene People
Charlie Galvin, General Manager, UK and Ireland, Amicus and Board Member, Association of British Pharmaceutical Industry
Tracey Bowden, Head of Policy and Public Affairs, MAP BioPharma
Break
12:30 – Lunch & Networking; Guided tours of MAP Online resources and free consultation clinics; Meet our exhibitors: NIHR Innovation Observatory (NIHRIO); O4 Research; EUCOPE
Session Three - Innovation tools
13:30 – Approaches to utilising Real World Evidence (RWE) – Andi Orlowski, Director of the Health Economics Unit (NHS)
14:00 – Collaborative working and Horizon Scanning – The NHS Long Term Plan and what this actually means for pharma companies - Jasdeep Hayre, Associate Director, Technology Appraisals, NICE
14:30 – Harnessing digital systems and technology to find new levels of patient value – Darren Spevick, Head of Europe, TSP and Chair of the EMIG Digital Health Special Interest Group
Break
15:00 – Refreshments & Networking; Guided tours of MAP Online resources and free consultation clinics; Meet our exhibitors: NIHR Innovation Observatory (NIHRIO); O4 Research; EUCOPE
Session Four - Pricing and policy
15:30 – VPAS – what you need to know – David Watson, Director Pricing And Reimbursement, Association of the British Pharmaceutical Industry (ABPI)
16:00 – Commercial and Managed Access in England – David Thomson, Associate Director – Commercial Liaison (PASLU), NICE
16:30 – Advanced Therapy Medicinal Products – Responding to new high cost/high value drugs
Outputs from ‘meet the expert’ sessions across Europe in 2020 – Christian Hill, Chief Executive Officer, MAP
17:00 – Conference Close – Networking Drinks Reception
Book Virtual Viewing Tickets
Note: This is an online viewing option for our London conference. A live stream broadcast will run throughout the day. The live link will be emailed to registered delegates 48 hours before the start of the event.
All registered attendees will have post event access to on-demand videos of each speaker session.
Copyright © 2021.
MAP BioPharma Limited.
All rights reserved.
MAP BioPharma Limited
Upper Pendrill Court, Ermine Street North
Papworth Everard, Cambridge
Cambridgeshire, CB23 3UY
United Kingdom
MAP BioPharma Limited is a registered company in England and Wales.
Company Registration Number 08209281
VAT Group Registration Number:
GB 292 8576 52